Compare Icl Group Ltd (ICL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Mesoblast Limited — how do they compare? Icl Group Ltd trades at $5.02 (market cap $6.47B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Icl Group Ltd is far larger — about 3.7× Mesoblast Limited's market cap, and Icl Group Ltd pays a 4.11% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Mesoblast Limited for 15 Days on average.
| ICL | MESO | |
|---|---|---|
Market Cap | $6.47B | $1.75B |
Volume | 1,387,140 | 239,027 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $20.96 |
52-Week Low | $4.80 | $13.19 |
Typical Hold Time | 56 Days | 15 Days |
Enterprise Value | $9.11B | $1.83B |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.00, down 1.57% today, with a bearish technical signal from moving averages but a neutral oscillator stance. Recent earnings beat estimates in Q1 and Q2 2026, though revenue and net income have trended lower from 2022 peaks. The company maintains a dividend, with a $0.06 payment scheduled for September 2026, and operates with stable cash flow from operations around $1.1 billion.
The outlook is mixed: valuation ratios like P/E of 20.83 and P/S of 0.84 suggest reasonable pricing, but analyst consensus is entirely Hold with a $6.08 target. Risks include industry headwinds from higher input costs and competitive pressures, while institutional buying, like Amundi's Q1 2026 purchase, offers support. Earnings growth and cost transformation are key to upside.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
